First reported study of daily, high dose transdermal application of oxybutynin in a humid country
Chung-Cheng Wang,
Ming-Huei Lee,
Yao-Chi Chuang,
Yung-Shun Juan,
Hsiang-Ying Lee,
Wei-Yu Lin,
Chun-Hou Liao,
Hann-Chorng Kuo
Affiliations
Chung-Cheng Wang
Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei City, Taiwan; Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan
Ming-Huei Lee
Department of Urology, Miaoli Hospital, Department of Health, Miaoli, Taiwan
Yao-Chi Chuang
Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Yung-Shun Juan
Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Hsiang-Ying Lee
Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
Wei-Yu Lin
Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi, Taiwan; Chang Gung University of Science and Technology, Chia-Yi, Taiwan
Chun-Hou Liao
Department of Urology, Cardinal Tien Hospital and School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan
Hann-Chorng Kuo
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Buddhist Tzu Chi University, Hualien, Taiwan; Correspondence to: Department of Urology, Hualien Tzu Chi Hospital, 707, Section 3, Chung-Yang Road, Hualien, 97002, Taiwan.
Objectives:: We investigated the efficacy and safety of a transdermal oxybutynin patch in treating patients with overactive bladder (OAB). Methods:: Ninety-three adult patients with OAB who were under stable treatment with antimuscarinic agents, mirabegron, or both for at least 1 month were prospectively recruited from seven hospitals in Taiwan. Patients who agreed to participate in the study stopped oral OAB medication for 2 weeks and started once-daily transdermal oxybutynin 75 mg. We evaluated the Overactive Bladder Symptom Score (OABSS), Patient Perception of Intensity of Urgency Scale (PPIUS), Patient Perception of Bladder Condition (PPBC), voiding diary, uroflowmetry, post-voiding residual urine, Global Response Assessment (GRA), and adverse events at baseline, 2 weeks, and 4 weeks. Results:: Mean patient age was 66.7 ± 14.8 years. Compared with the measurements at baseline, the GRA, OABSS, PPIUS, PPBC, urinary urgency incontinence, urgency, and frequency significantly improved after 2 and 4 weeks of treatment. At 4 weeks, 20 patients (25%) reported markedly improvement (GRA = +3), 11 (13.8%) reported moderate improvement (GRA = +2), and 28 (35%) reported mild improvement (GRA = +1). Patients with GRA ≥ 1 had a significantly less proportion of oral combination therapy compared with those with GRA < 1 (5/59, 8.5% vs 8/21, 38.1%, p < 0.01). Common adverse events included skin itching in 34 (36.6%) patients, dry mouth in 20 (21.5%), and erythema in 7 (7.5%). Conclusion:: The transdermal oxybutynin patch was effective and safe in the treatment of patients with OAB after switching from oral OAB medications.
